{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:31:48Z","timestamp":1790303508675,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"M.D. Anderson Cancer Center","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"name":"NIH","award":["P01 CA049639"],"award-info":[{"award-number":["P01 CA049639"]}]},{"DOI":"10.13039\/100006413","name":"Ariad","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"name":"Chemgenex"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2014.01.003","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T04:49:31Z","timestamp":1389761371000},"page":"327-334.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangbum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.01.003_bib1","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 2.2012. \u00a9 2012 National Comprehensive Cancer Network, Inc. Available at: https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed December 1,\u00a02011."},{"key":"10.1016\/j.clml.2014.01.003_bib2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.01.003_bib4","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.003_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ssu.2980100103","article-title":"On the estimation of survival","volume":"10","author":"Henson","year":"1994","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.01.003_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6506","article-title":"Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib","volume":"30","author":"Shah","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib8","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2003.04.521","article-title":"Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark","volume":"21","author":"Skuladottir","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib9","first-page":"1","article-title":"An R package for the joint modelling of longitudinal and time-to-event data","volume":"35","author":"Rizopoulos","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.clml.2014.01.003_bib10","first-page":"809","article-title":"Joint modeling of longitudinal and time-to-event data: an overview","volume":"14","author":"Tsiatis","year":"2004","journal-title":"Stat Sin"},{"key":"10.1016\/j.clml.2014.01.003_bib11","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1200\/JCO.2009.23.1860","article-title":"Practical application of a calculator for conditional survival in colon cancer","volume":"27","author":"Chang","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib12","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2009.23.0573","article-title":"Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07","volume":"28","author":"Zamboni","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.01.003_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5694\/j.1326-5377.2011.tb04171.x","article-title":"When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects","volume":"194","author":"Baade","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.clml.2014.01.003_bib14","first-page":"21","article-title":"Conditional survival analyses across cancer sites","volume":"22","author":"Ellison","year":"2011","journal-title":"Health Rep"},{"key":"10.1016\/j.clml.2014.01.003_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/1471-2407-12-460","article-title":"Conditional survival of cancer patients: an Australian perspective","volume":"12","author":"Yu","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2014.01.003_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2012.311","article-title":"Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies","volume":"27","author":"Vanderwalde","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.01.003_bib17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.01.003_bib18","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:41Z","timestamp":1761870341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265014000044"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Outcomes in Patients With Chronic Myeloid Leukemia at Any Time During Tyrosine Kinase Inhibitor Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}